Kyounghyun Kim

High Impact

Assistant Professor

UAMS

Also affiliated: University of North Carolina at Chapel Hill (2024); Texas Tech University (2009); Texas A&M Health Science Center (2009–2025); The University of Texas MD Anderson Cancer Center (2010); Seoul National University (2022); Chungbuk National University (2006); Eli Lilly (United States) (2012); Texas A&M University System (2006–2008); Yonsei University (2004); Korea University (1999–2023); Severance Hospital (2022); Korea University Medical Center (1999); HCA Healthcare (2009); Asan Medical Center (2011); University of California San Diego (2007); The Institute of Medical Science, Asahi Life Foundation (2007); National Cancer Center (2010–2023); CHA University (2013); Yonsei University Health System (2004); Korea University Anam Hospital (1999); Hanyang University (2001); University of Cincinnati (2011–2021); Lanzhou University (2009); Newcastle University (2007); The University of Texas Southwestern Medical Center (2019); Catholic Kwandong University (2001); Texas A&M University (1993–2019)

COM | Pharmacology & Toxicology

29 h-index 107 pubs 5,555 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Kyounghyun Kim's research focuses on the molecular mechanisms underlying various diseases, with a particular emphasis on cancer. Dr. Kim investigates how specific transcription factors, such as Sp1, influence gene expression in the context of neoplastic growth. His work has explored the role of the androgen receptor in regulating GPER1 transcription in prostate cancer cells and how the loss of the orphan nuclear receptor NR2E3 impacts Wnt/β-catenin signaling in hepatocellular carcinoma through epigenetic modifications and interactions with Sp1 and p300.

Further research by Dr. Kim extends to the influence of endocrine-disrupting chemicals on pancreatic diseases and cancer, examining the activity of the aryl hydrocarbon receptor. His publications also address broader health topics, including the association between body composition and chronic rhinosinusitis, and the contribution of type 2 diabetes mellitus to cardiovascular outcomes in cancer survivors. Dr. Kim leads a research group at the University of Arkansas for Medical Sciences and has an h-index of 32 with over 6,300 citations across 132 publications.

Metrics

h-index: 29
Publications: 107
Citations: 5,555

Positions

Assistant Professor 2013–present

University of Arkansas for Medical Sciences COM | Pharmacology & Toxicology Institutional directory

Selected Publications

Dual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling (2026)

International Journal of Molecular Sciences 1 citation DOI OpenAlex
Abstract 1276: Dual epigenetic-kinase targeting to overcome resistance and immune evasion in hepatocellular carcinoma. (2026)

Cancer Research DOI OpenAlex
Abstract 440: Dual epigenetic targeting of hepatocellular carcinoma (2025)

Cancer Research DOI OpenAlex
The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β‐catenin Signaling via Epigenetic Dysregulation that Enhances Sp1‐β catenin‐p300 Interactions in Hepatocellular Carcinoma (2024)

Advanced Science 9 citations DOI OpenAlex
The Role of Endocrine Disruption Chemical-Regulated Aryl Hydrocarbon Receptor Activity in the Pathogenesis of Pancreatic Diseases and Cancer (2024)

International Journal of Molecular Sciences 24 citations DOI OpenAlex
Abstract 3011: The loss of an orphan nuclear receptor NR2E3 augments Wnt/β-Catenin signaling via epigenetic dysregulation that links to the Sp1-β catenin-p300 interactions in hepatocellular carcinoma (2024)

Cancer Research DOI OpenAlex